Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) VP Jeffrey T. L. Smith sold 3,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $31.14, for a total value of $93,420.00. Following the sale, the vice president now directly owns 3,000 shares in the company, valued at approximately $93,420. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) opened at 30.33 on Monday. The company’s 50 day moving average price is $32.28 and its 200 day moving average price is $28.47. The firm’s market cap is $1.52 billion. Alder BioPharmaceuticals Inc. has a 12-month low of $15.82 and a 12-month high of $39.43.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $1.14 million. The company’s revenue for the quarter was up 112900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.46) earnings per share. Equities research analysts forecast that Alder BioPharmaceuticals Inc. will post ($3.33) EPS for the current year.
Several large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its stake in shares of Alder BioPharmaceuticals by 110.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,844 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 2,016 shares during the last quarter. Birchview Capital LP acquired a new stake in shares of Alder BioPharmaceuticals during the second quarter worth about $129,000. Teacher Retirement System of Texas boosted its stake in shares of Alder BioPharmaceuticals by 85.5% in the second quarter. Teacher Retirement System of Texas now owns 5,393 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 2,485 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Alder BioPharmaceuticals during the second quarter worth about $206,000. Finally, Legal & General Group Plc boosted its stake in shares of Alder BioPharmaceuticals by 57.6% in the first quarter. Legal & General Group Plc now owns 8,349 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,053 shares during the last quarter.
A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Alder BioPharmaceuticals in a research report on Tuesday, September 13th. They set an “overweight” rating and a $40.00 price target on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $61.00 target price on shares of Alder BioPharmaceuticals in a report on Tuesday, July 19th. Brean Capital reaffirmed a “positive” rating and issued a $45.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, July 27th. Finally, Zacks Investment Research downgraded Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Seven investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $45.00.
Alder BioPharmaceuticals Company Profile
Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.